{"id":"NCT03745716","sponsor":"Aprea Therapeutics","briefTitle":"APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)","officialTitle":"A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination With Azacitidine Versus Azacitidine Alone for the Treatment of (Tumor Protein) TP53 Mutant Myelodysplastic Syndromes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-11","primaryCompletion":"2020-11-27","completion":"2022-01-14","firstPosted":"2018-11-19","resultsPosted":"2022-07-12","lastUpdate":"2025-03-18"},"enrollment":154,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["MDS"],"interventions":[{"type":"DRUG","name":"APR-246 + azacitidine","otherNames":[]},{"type":"DRUG","name":"Azacitidine","otherNames":[]}],"arms":[{"label":"Experimental arm: APR-246 + azacitidine","type":"EXPERIMENTAL"},{"label":"Control arm: Azacitidine","type":"EXPERIMENTAL"}],"summary":"A Phase III, multicenter, randomized study to compare the rate of complete response (CR) and duration of CR, in patients with TP53-mutated MDS who will receive APR-246 and azacitidine or azacitidine alone.","primaryOutcome":{"measure":"Complete Response Rate (CR)","timeFrame":"12 months","effectByArm":[{"arm":"Experimental Arm: APR-246 + Azacitidine","deltaMin":27,"sd":null},{"arm":"Control Arm: Azacitidine","deltaMin":17,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":27,"countries":["United States","France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":53,"n":76},"commonTop":["Constipation","Nausea","Anemia","White blood cell count decreased","Neutrophil count decreased"]}}